Personal information

Emails & domains

Verified email domains

Activities

Collapse all

Employment (1)

Heinrich Heine University: Düsseldorf, NRW, DE

Professor and Chairman (Neurology)
Employment
Source: Self-asserted source
Hans-Peter Hartung

Education and qualifications (1)

Heinrich-Heine-University Duesseldorf: Duesseldorf, NRW, DE

2001-10-01 to present | Professor and Chairman (Neurology)
Qualification
Source: Self-asserted source
Hans-Peter Hartung

Professional activities (1)

Heinrich-Heine-University Duesseldorf: Duesseldorf, NRW, DE

2001-12-01 to present | Professor and Chairman (Neurology)
Invited position
Source: Self-asserted source
Hans-Peter Hartung

Works (28)

Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis

Cells
2025-04 | Journal article | Author
DOI: 10.3390/cells14070552
Contributors: Alice Willison; Ramona Hagler; Margit Weise; Saskia Elben; Niklas Huntemann; Lars Masanneck; Steffen Pfeuffer; Stefanie Lichtenberg; Kristin S. Golombeck; Lara-Maria Preuth et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis

Neurology
2024-12-24 | Journal article
DOI: 10.1212/WNL.0000000000210049
Contributors: Hans-Peter Hartung; Ralph H.B. Benedict; Thomas Berger; Robert A. Bermel; Bruno Brochet; William M. Carroll; Mark S. Freedman; Trygve Holmøy; Rana Karabudak; Carlos Nos et al.
Source: check_circle
Crossref

ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial

Journal of Neurology
2024-07 | Journal article
DOI: 10.1007/s00415-024-12326-z
Contributors: Hans-Peter Hartung; Thomas Berger; Robert A. Bermel; Bruno Brochet; William M. Carroll; Trygve Holmøy; Rana Karabudak; Joep Killestein; Carlos Nos; Francesco Patti et al.
Source: check_circle
Crossref

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis

Neurology
2024-05-14 | Journal article
DOI: 10.1212/WNL.0000000000209357
Contributors: Robert J. Fox; Bruce A.C. Cree; Jérôme de Sèze; Ralf Gold; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Xavier Montalban; Bianca Weinstock-Guttman; Carol M. Singh et al.
Source: check_circle
Crossref

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis

Therapeutic Advances in Neurological Disorders
2024-01 | Journal article
DOI: 10.1177/17562864241233041
Contributors: Laura Airas; Robert A. Bermel; Tanuja Chitnis; Hans-Peter Hartung; Jin Nakahara; Olaf Stuve; Mitzi J. Williams; Bernd C. Kieseier; Heinz Wiendl
Source: check_circle
Crossref

Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials

Therapeutic Advances in Neurological Disorders
2024-01 | Journal article
DOI: 10.1177/17562864241277736
Contributors: Tobias Derfuss; Robert Bermel; Chien-Ju Lin; Stephen L. Hauser; Ludwig Kappos; Timothy Vollmer; Giancarlo Comi; Gavin Giovannoni; Hans-Peter Hartung; Martin S. Weber et al.
Source: check_circle
Crossref

SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis

Annals of Clinical and Translational Neurology
2023-10 | Journal article
DOI: 10.1002/acn3.51862
Contributors: Bruce A. C. Cree; Rachel Maddux; Amit Bar‐Or; Hans‐Peter Hartung; Amandeep Kaur; Elizabeth Brown; Yicong Li; Yanhua Hu; James K. Sheffield; Diego Silva et al.
Source: check_circle
Crossref

Transgenic expression of the HERV-W envelope protein leads to polarized glial cell populations and a neurodegenerative environment

Proceedings of the National Academy of Sciences
2023-09-19 | Journal article
DOI: 10.1073/pnas.2308187120
Contributors: Joel Gruchot; Isabel Lewen; Michael Dietrich; Laura Reiche; Mustafa Sindi; Christina Hecker; Felisa Herrero; Benjamin Charvet; Ulrike Weber-Stadlbauer; Hans-Peter Hartung et al.
Source: check_circle
Crossref

An innovative phase 2 proof‐of‐concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy

Journal of the Peripheral Nervous System
2023-06 | Journal article
DOI: 10.1111/jns.12551
Contributors: Luis Querol; Richard A. Lewis; Hans‐Peter Hartung; Pieter A. Van Doorn; Erik Wallstroem; Xiaodong Luo; Miguel Alonso‐Alonso; Nazem Atassi; Richard A. C. Hughes
Source: check_circle
Crossref

Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis

Journal of Neurology
2022-07 | Journal article
DOI: 10.1007/s00415-022-11158-z
Contributors: A. G. Willison; T. Ruck; G. Lenz; H. P. Hartung; S. G. Meuth
Source: check_circle
Crossref

The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis

Journal of Neurology
2022-07 | Journal article
DOI: 10.1007/s00415-022-11063-5
Contributors: A. G. Willison; T. Ruck; G. Lenz; H. P. Hartung; S. G. Meuth
Source: check_circle
Crossref

Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy

Journal of the Peripheral Nervous System
2022-06 | Journal article
DOI: 10.1111/jns.12487
Contributors: Ingemar S. J. Merkies; Ivo N. van Schaik; Vera Bril; Hans‐Peter Hartung; Richard A. Lewis; Gen Sobue; John‐Philip Lawo; Orell Mielke; David R. Cornblath
Source: check_circle
Crossref

Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents

Journal of Neurology
2022-05 | Journal article
DOI: 10.1007/s00415-021-10956-1
Contributors: Melanie Korsen; Steffen Pfeuffer; Leoni Rolfes; Sven G. Meuth; Hans-Peter Hartung
Source: check_circle
Crossref

Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management

Neurotherapeutics
2022-04 | Journal article
DOI: 10.1007/s13311-022-01224-9
Contributors: Nik Krajnc; Gabriel Bsteh; Thomas Berger; Jan Mares; Hans-Peter Hartung
Source: check_circle
Crossref

Correction to “Hartung H‐P. Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision‐Making.”

Annals of Neurology
2021-12 | Journal article
DOI: 10.1002/ana.26243
Contributors: Hans‐Peter Hartung
Source: check_circle
Crossref

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk

Neurotherapeutics
2021-07 | Journal article
DOI: 10.1007/s13311-021-01102-w
Contributors: Hans-Peter Hartung; Jan Mares; Sven G. Meuth; Thomas Berger
Source: check_circle
Crossref

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

Journal of Neurology
2021-07-08 | Journal article
DOI: 10.1007/s00415-019-09690-6
Contributors: F. Schweitzer; S. Laurent; G. R. Fink; Michael H. Barnett; H. P. Hartung; C. Warnke
Source: check_circle
Crossref

Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision‐Making

Annals of Neurology
2021-06 | Journal article
DOI: 10.1002/ana.26087
Contributors: Hans‐Peter Hartung
Source: check_circle
Crossref

Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets

Therapeutic Advances in Neurological Disorders
2021-01 | Journal article
DOI: 10.1177/17562864211019598
Contributors: Ralf Gold; Gerd Fätkenheuer; Hans-Peter Hartung; Christoph Kleinschnitz; Reinhard Marks; Matthias Maschke; Antonios Bayas; Micha Löbermann; Uwe K. Zettl; Heinz Wiendl
Source: check_circle
Crossref

Resolving the transcriptional transitions associated with oligodendrocyte generation from adult neural stem cells by single cell sequencing

2020-12-20 | Other
DOI: 10.1101/2020.12.18.423285
Contributors: Kasum Azim; Filippo Calzolari; Martina Cantone; Rainer Akkermann; Julio Vera; Hans-Peter Hartung; Onur Basak; Arthur Morgan Butt; Patrick Küry
Source: check_circle
Crossref

Ocrelizumab shorter infusion

Neurology Neuroimmunology & Neuroinflammation
2020-09-03 | Journal article
DOI: 10.1212/NXI.0000000000000807
Contributors: Hans-Peter Hartung
Source: check_circle
Crossref

Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis

Neurology
2020-06-02 | Journal article
DOI: 10.1212/WNL.0000000000009522
Contributors: Nils C. Landmeyer; Paul-Christian Bürkner; Heinz Wiendl; Tobias Ruck; Hans-Peter Hartung; Heinz Holling; Sven G. Meuth; Andreas Johnen
Source: check_circle
Crossref

Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study

Journal of Neurology
2020-02-04 | Journal article
DOI: 10.1007/s00415-018-09169-w
Contributors: Hans-Peter Hartung; Jonas Graf; David Kremer
Source: check_circle
Crossref

Patient‐reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study

European Journal of Neurology
2020-01 | Journal article
DOI: 10.1111/ene.14056
Contributors: H.‐P. Hartung; R. Mallick; V. Bril; R. A. Lewis; G. Sobue; J.‐P. Lawo; O. Mielke; B. L. Durn; D. R. Cornblath; I. S. J. Merkies et al.
Source: check_circle
Crossref

Drug Treatment of Clinically Isolated Syndrome

CNS Drugs
2019-07-01 | Journal article
DOI: 10.1007/s40263-019-00647-x
Contributors: Moritz Förster; Jonas Graf; Jan Mares; Orhan Aktas; Hans-Peter Hartung; David Kremer
Source: check_circle
Crossref

Managing Risks with Immune Therapies in Multiple Sclerosis

Drug Safety
2019-05-03 | Journal article
DOI: 10.1007/s40264-018-0782-8
Contributors: Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Source: check_circle
Crossref

Monoclonal Antibodies for Multiple Sclerosis: An Update

BioDrugs
2019-02-02 | Journal article
DOI: 10.1007/s40259-018-0327-9
Contributors: Jonas Graf; Orhan Aktas; Konrad Rejdak; Hans-Peter Hartung
Source: check_circle
Crossref

Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond

CNS Drugs
2018-07-10 | Journal article
DOI: 10.1007/s40263-018-0536-2
Contributors: Verena Isabell Leussink; Xavier Montalban; Hans-Peter Hartung
Source: check_circle
Crossref
How many people are using ORCID?